LIVIVO - Search results -

Search results

Result 1 - 10 of total 25

Search options

Article ; Online: Simultaneous pathological findings in biopsy specimens of patients with surgically resected lung carcinoids and their role in survival.

Georgakopoulou, Vasiliki Epameinondas / Zygouris, Eleftherios / Papalexis, Petros / Gkoufa, Aikaterini / Damaskos, Christos / Pierrakou, Aikaterini / Mantzouranis, Konstantinos / Chlapoutakis, Serafeim / Aravantinou-Fatorou, Aikaterini / Sklapani, Pagona / Trakas, Nikolaos / Janinis, Jim / Dahabreh, Jubrail / Spandidos, Demetrios A

Oncology letters

2022 Volume 24, Issue 3, Page(s) 313

Abstract: Pulmonary carcinoid tumors are rare, low-grade malignant tumors that constitute 1-2% of all lung tumors. The present study aimed to describe the simultaneous pathological findings in biopsy specimens of patients with surgically resected lung carcinoids ... ...

Abstract	Pulmonary carcinoid tumors are rare, low-grade malignant tumors that constitute 1-2% of all lung tumors. The present study aimed to describe the simultaneous pathological findings in biopsy specimens of patients with surgically resected lung carcinoids and determine their association with survival rates. For this purpose, 108 patients with resected carcinoid lung tumors were followed-up for 96 months and analyzed for simultaneous pathological findings in biopsy specimens. Among these, simultaneous pathological findings were found in 82 patients. The association between these findings and patient survival rates was evaluated. Atelectasis was a simultaneous finding in 52.4% of the patients, desquamative interstitial pneumonia (DIP) in 13.4%, emphysema in 24.4% and bronchiectasis in 9.8%. The survival rate was 100% for the patients with atelectasis, 81.8% for the patients with DIP, 90% for the patients with emphysema and 75% for the patients with bronchiectasis (P<0.05). According to the univariate analysis, the type of carcinoid was associated with patient survival with better survival rates for patients with typical carcinoids, while age, sex, stage and simultaneous pathological findings were not associated with patient survival. On the whole, there was a statistically significant difference in the survival rates of patients with resected lung carcinoids with different simultaneous pathological findings. However, further studies are warranted to assess the role of these findings in the survival of these patients.
Language	English
Publishing date	2022-07-15
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2573196-8
ISSN	1792-1082 ; 1792-1074
ISSN (online)	1792-1082
ISSN	1792-1074
DOI	10.3892/ol.2022.13433
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Predictive Indicators of Survival in Patients With Surgically Resected Lung Carcinoid Tumors at a Greek Medical Center.

Georgakopoulou, Vasiliki E / Zygouris, Eleftherios / Nikokiris, Christos / Damaskos, Christos / Pierrakou, Aikaterini / Garmpis, Nikolaos / Garmpi, Anna / Sklapani, Pagona / Aravantinou, Aikaterini / Trakas, Nikolaos / Janinis, Jim / Dahabreh, Jubrail

Cureus

2020 Volume 12, Issue 9, Page(s) e10300

Abstract: Introduction Lung carcinoid tumors are neuroendocrine neoplasms, less frequent than other lung tumors. They are subdivided into typical carcinoids (TC) and atypical carcinoids (AC), according to the rate of mitosis and the presence of necrosis. Lung ... ...

Abstract	Introduction Lung carcinoid tumors are neuroendocrine neoplasms, less frequent than other lung tumors. They are subdivided into typical carcinoids (TC) and atypical carcinoids (AC), according to the rate of mitosis and the presence of necrosis. Lung carcinoids are often asymptomatic and only discovered incidentally. They may also present with cough, wheezing, asthma, and chronic obstructive pulmonary disease, chest pain, and hemoptysis depending on the location of the tumor and, less commonly, present with carcinoid syndrome. In our study, we describe the clinical and pathological features of patients with surgically resected lung carcinoids at our institution over a period of 14 years. We also examine if these features, including age, gender, tumor size, type of carcinoid, stage, nodal involvement, and Ki-67 expression are associated with patients' survival. Materials and methods We retrospectively reviewed patients that underwent surgery with a final histologic diagnosis of a pulmonary carcinoid tumor from March 2005 to March 2019. The evaluation included history, physical examination, chest radiographs, computerized tomography of the chest, upper abdomen, and brain, and bone scintiscan. All specimens resected during the surgical procedures were sent for pathological examination, including mediastinal and hilar lymph nodes. The patients' age, gender, tumor size, type of carcinoid, nodal involvement, stage, and Ki-67 expression were recorded and correlated to the patients' survival rates. Results The study included 108 patients - 52 males and 56 females - with a mean age of 51.5 years (range 11-80 years). Atypical carcinoid was the diagnosis in 28 patients (16 males and 12 females) and 80 patients had the diagnosis of typical carcinoid (36 males and 44 females). Tumor size was ≤3.7 cm in 84 patients (68 with TC and 16 with AC) and >3.7 cm in 22 patients (12 with TC and 10 with AC). Sixteen patients had nodal deposits, 12 in N1 nodes and four in N2 nodes. Eighty patients were classified in stage I, 18 patients in stage II, and 10 patients in stage III. None of the patients had distant metastases. The Ki-67 proliferation index was examined in 84 specimens and Ki-67 was <2.5 in 50 patients and ≥2.5 in 34 patients. Of the 108 patients, eight died, all with disease-related death. According to the Cox regression univariate analysis, four factors were correlated to shorter survival: atypical histology, tumor size >3.7 cm, nodal involvement, and advanced stage Conclusions In conclusion, we found that histological type, tumor size, nodal involvement, and stage are associated with survival in patients with surgically resected lung carcinoids without distant metastases. Other parameters, such as age at operation, gender, and Ki-67 index, did not have a role in survival in these patients according to the Cox regression univariate analysis.
Language	English
Publishing date	2020-09-07
Publishing country	United States
Document type	Journal Article
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.10300
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prognostic value of the immunohistochemistry markers CD56, TTF-1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors.

Georgakopoulou, Vasiliki Epameinondas / Zygouris, Eleftherios / Damaskos, Christos / Pierrakou, Aikaterini / Papalexis, Petros / Garmpis, Nikolaos / Aravantinou-Fatorou, Aikaterini / Chlapoutakis, Serafeim / Diamantis, Evangelos / Nikokiris, Christos / Gkoufa, Aikaterini / Sklapani, Pagona / Trakas, Nikolaos / Janinis, Jim / Spandidos, Demetrios A / Dahabreh, Jubrail

Molecular and clinical oncology

2021 Volume 16, Issue 2, Page(s) 31

Abstract: Lung carcinoid tumor is a type of neuroendocrine tumor, which is subdivided into typical carcinoid (TC) and atypical carcinoid (AT), based on the rate of mitosis and the presence of necrosis. Several prognostic factors for lung carcinoids have been ... ...

Abstract	Lung carcinoid tumor is a type of neuroendocrine tumor, which is subdivided into typical carcinoid (TC) and atypical carcinoid (AT), based on the rate of mitosis and the presence of necrosis. Several prognostic factors for lung carcinoids have been reported in the literature, including the type, Ki67 index, stage, chemotherapy and radiation therapy. In the present study, 108 cases with resected carcinoid lung tumors were enrolled and the expression of CD56, thyroid transcription factor 1, synaptophysin, carcinoembryonic antigen, epithelial membrane antigen and neuron-specific enolase (NSE) in the resected tissue specimens was immunohistochemically analyzed. Patients with positive staining for NSE had an unfavorable survival prognosis compared with patients with negative staining for NSE (137.2 vs. 150.0 months, P=0.044). According to univariate analysis, none of the above immunohistochemistry markers was associated with survival, and according to multivariate analysis, NSE was an independent influencing factor for survival inpatients with AT (P=0.046) and furthermore, the stage was an independent factor of survival in patients with TC (P=0.005).
Language	English
Publishing date	2021-12-14
Publishing country	England
Document type	Journal Article
ZDB-ID	2796865-0
ISSN	2049-9469 ; 2049-9450
ISSN (online)	2049-9469
ISSN	2049-9450
DOI	10.3892/mco.2021.2464
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Docetaxel, cisplatin, fluorouracil, and leucovorin in locally advanced head and neck cancer.

Janinis, J / Panagos, G

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2000 Volume 18, Issue 6, Page(s) 1393–1395

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin/administration & dosage ; Fluorouracil/administration & dosage ; Head and Neck Neoplasms/drug therapy ; Humans ; Leucovorin/administration & dosage ; Paclitaxel/administration & dosage ; Paclitaxel/analogs & derivatives ; Taxoids/analogs & derivatives
Chemical Substances	Taxoids ; Paclitaxel (P88XT4IS4D) ; Cisplatin (Q20Q21Q62J) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2000-03
Publishing country	United States
Document type	Comment ; Letter
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.2000.18.6.1393
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Surgical resection of esthesioneuroblastoma metastasis to the chest wall.

Dahabreh, Issa / Janinis, Dimitrios / Stamatelopoulos, Athanassios G / Bontozoglou, Nikolaos / Dahabreh, Jubrail

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

2007 Volume 2, Issue 1, Page(s) 93–95

Abstract: A 51-year-old female patient was evaluated for a painful chest wall mass causing atelectasis of the right lung, pleural effusion, and dyspnea. The patient's history was significant for esthesioneuroblastoma at the age of 24; multiple recurrences of the ... ...

Abstract	A 51-year-old female patient was evaluated for a painful chest wall mass causing atelectasis of the right lung, pleural effusion, and dyspnea. The patient's history was significant for esthesioneuroblastoma at the age of 24; multiple recurrences of the tumor had been treated with surgery, radiotherapy, and chemotherapy. Surgical resection of the chest wall mass relieved her symptoms and improved her quality of life. Histologic examination confirmed metastatic esthesioneuroblastoma. The patient developed generalized disease and finally died 2 years after surgery. This case demonstrates the long natural history of this rare neoplasm and the need for close follow-up of patients so that they can be treated early.
MeSH term(s)	Esthesioneuroblastoma, Olfactory/secondary ; Esthesioneuroblastoma, Olfactory/surgery ; Female ; Humans ; Middle Aged ; Nasal Cavity ; Nose Neoplasms/pathology ; Nose Neoplasms/surgery ; Thoracic Neoplasms/secondary ; Thoracic Neoplasms/surgery ; Thoracic Wall
Language	English
Publishing date	2007-01
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2432037-7
ISSN	1556-1380 ; 1556-0864
ISSN (online)	1556-1380
ISSN	1556-0864
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6664: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 652: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunohistochemical expression of placental alkaline phosphatase and vimentin in epithelial ovarian neoplasms.

Nakopoulou, L / Stefanaki, K / Janinis, J / Mastrominas, M

Acta oncologica (Stockholm, Sweden)

1995 Volume 34, Issue 4, Page(s) 511–515

Abstract: The immunohistochemical expression of PLAP and vimentin was assessed in 23 benign, 6 borderline malignant and 31 malignant epithelial ovarian neoplasms. PLAP and vimentin were expressed in some benign (3/23 and 5/23 respectively) and borderline malignant ...

Abstract	The immunohistochemical expression of PLAP and vimentin was assessed in 23 benign, 6 borderline malignant and 31 malignant epithelial ovarian neoplasms. PLAP and vimentin were expressed in some benign (3/23 and 5/23 respectively) and borderline malignant (2/6 for both markers) tumours and they were often expressed in malignant tumours (16/31 and 17/31 respectively). There was a significantly increased expression of PLAP and vimentin in serous cystadenomas and serous carcinomas compared to their mucinous counterparts. Although there was no significant correlation between PLAP expression and histologic grade of carcinomas there was a trend towards increased expression in more differentiated carcinomas. No correlation was found between vimentin expression and degree of differentiation.
MeSH term(s)	Adult ; Aged ; Alkaline Phosphatase/biosynthesis ; Biomarkers, Tumor/metabolism ; Carcinoma/enzymology ; Carcinoma/metabolism ; Female ; GPI-Linked Proteins ; Gene Expression ; Humans ; Isoenzymes/biosynthesis ; Middle Aged ; Ovarian Neoplasms/enzymology ; Ovarian Neoplasms/metabolism ; Placenta/enzymology ; Vimentin/biosynthesis
Chemical Substances	Biomarkers, Tumor ; GPI-Linked Proteins ; Isoenzymes ; Vimentin ; Alkaline Phosphatase (EC 3.1.3.1) ; alkaline phosphatase, placental (EC 3.1.3.1)
Language	English
Publishing date	1995
Publishing country	England
Document type	Journal Article
ISSN	0284-186X
ISSN	0284-186X
DOI	10.3109/02841869509094016
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The pharmacological treatment of aggressive fibromatosis: a systematic review.

Janinis, J / Patriki, M / Vini, L / Aravantinos, G / Whelan, J S

Annals of oncology : official journal of the European Society for Medical Oncology

2003 Volume 14, Issue 2, Page(s) 181–190

Abstract: Background: Despite the use of surgery and radiotherapy, 20-35% of patients with aggressive fibromatosis (AF) will have local recurrence. The purpose of this review was to collect and analyze all available information regarding the role of non-cytotoxic ...

Abstract	Background: Despite the use of surgery and radiotherapy, 20-35% of patients with aggressive fibromatosis (AF) will have local recurrence. The purpose of this review was to collect and analyze all available information regarding the role of non-cytotoxic and cytotoxic chemotherapy in AF that has been accumulated over the past few decades. Patients and methods: A systematic review of published clinical trials, studies and case series was carried out using the Medline Express Databases and the Cochrane Collaboration Database from 1970 to October 2000. Results: Most studies published in the literature are in the form of successful case reports and single-arm series with small patient numbers. Most commonly used agents include hormonal agents, non-steroidal anti-inflammatory drugs (NSAIDs), interferons and cytotoxics. The literature data support the use of hormonal agents. Several questions, however, remain unresolved, such as which is the most suitable endocrine manipulation and what is the optimal dose and duration of treatment. NSAIDs and interferons have demonstrated activity against AF either alone or in combination with hormone therapy or chemotherapy but the precise mechanism of action is still unknown. Finally, there is growing evidence in the literature that chemotherapy is effective against AF with almost one in two patients being likely to respond. Conclusions: The evidence in the literature supports the opinion that both non-cytotoxic and cytotoxic chemotherapies are effective against AF. However, the lack of sufficient patient numbers and randomized trials compromises the validity of the reported results and mandates further investigation with properly designed prospective studies including larger patient numbers, with main end points to include not only tumor response rate and survival but also quality-of-life issues.
MeSH term(s)	Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Clinical Trials as Topic ; Fibroma/drug therapy ; Fibroma/pathology ; Humans ; Prognosis ; Survival
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Antineoplastic Agents, Hormonal
Language	English
Publishing date	2003-02
Publishing country	England
Document type	Journal Article ; Review ; Systematic Review
ZDB-ID	1025984-3
ISSN	1569-8041 ; 0923-7534
ISSN (online)	1569-8041
ISSN	0923-7534
DOI	10.1093/annonc/mdg064
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2862: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunohistochemical expression of EGF-R in malignant surface epithelial ovarian neoplasms (SEON).

Janinis, J / Nakopoulou, L / Panagos, G / Davaris, P

European journal of gynaecological oncology

1994 Volume 15, Issue 1, Page(s) 19–23

Abstract: EGF-R expression was found to be increased in 40% of malignant epithelial ovarian neoplasms by an immunohistochemical method. No correlation was found between EGF-R expression and clinical stage. There was a suggestion of reduced survival among tumours ... ...

Abstract	EGF-R expression was found to be increased in 40% of malignant epithelial ovarian neoplasms by an immunohistochemical method. No correlation was found between EGF-R expression and clinical stage. There was a suggestion of reduced survival among tumours with positive EGF-R expression.
MeSH term(s)	Aged ; Carcinoma/genetics ; Carcinoma/pathology ; Carcinoma, Endometrioid/genetics ; Carcinoma, Endometrioid/pathology ; Cell Membrane/ultrastructure ; Cytoplasm/ultrastructure ; Epithelium/pathology ; ErbB Receptors/analysis ; ErbB Receptors/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Prognosis ; Retrospective Studies ; Survival Rate
Chemical Substances	ErbB Receptors (EC 2.7.10.1)
Language	English
Publishing date	1994
Publishing country	China
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	604589-3
ISSN	0392-2936
ISSN	0392-2936
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1679: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A systematic review of the role of pulmonary irradiation in the management of primary bone tumours.

Whelan, J S / Burcombe, R J / Janinis, J / Baldelli, A M / Cassoni, A M

Annals of oncology : official journal of the European Society for Medical Oncology

2002 Volume 13, Issue 1, Page(s) 23–30

Abstract: Introduction: Adjuvant therapy in osteosarcoma (OS) and Ewing's sarcoma (ES) is primarily directed towards treatment of subclinical lung disease. Before the advent of modern intensive chemotherapy, lung irradiation was the only available adjuvant ... ...

Abstract	Introduction: Adjuvant therapy in osteosarcoma (OS) and Ewing's sarcoma (ES) is primarily directed towards treatment of subclinical lung disease. Before the advent of modern intensive chemotherapy, lung irradiation was the only available adjuvant treatment. It has proven biological activity and low morbidity. There is, however, a wide variation in its application between centres. This systematic review aims to define the evidence to support the use of lung irradiation in these diseases. Design: A review of trials published between 1966 and 2000 was undertaken to determine the evidence for the use of pulmonary irradiation in OS and ES. Results: Several small series of prophylactic lung irradiation (PLI) have been reported, most from over 20 years ago. These studies support the theoretical basis for the use of PLI in both OS and ES. Few randomised studies have been performed which include PLI. In OS, studies demonstrated a trend in favour of PLI compared with no adjuvant treatment and, subsequently, a level of benefit similar to that achieved with chemotherapy, but no additive effect. No studies have used PLI in addition to current standard chemotherapy regimens, or evaluated its use after successful metastatectomy. In ES, only one randomised study has addressed the role of PLI, in a comparison with vincristine, actinomycin D and cyclophosphamide combination chemotherapy with or without doxorubicin. Prolonged follow-up favoured four-drug chemotherapy. Retrospective reports from large cooperative groups suggest that the addition of whole-lung radiotherapy (WLRT) improves outcome in ES patients presenting with pulmonary metastases. However, there are no randomised study data to support this. Conclusions: Further randomised studies are necessary to clarify the role of PLI in addition to current standard chemotherapy regimens, or its use after successful metastasectomy in patients with OS. In patients with localised ES adjuvant chemotherapy appears to be superior to PLI alone, while there is little evidence to support treatment with WLRT in patients who present with pulmonary metastases.
MeSH term(s)	Bone Neoplasms/pathology ; Bone Neoplasms/radiotherapy ; Humans ; Lung Neoplasms/prevention & control ; Lung Neoplasms/radiotherapy ; Lung Neoplasms/secondary ; Neoplasm Metastasis/prevention & control ; Osteosarcoma/pathology ; Osteosarcoma/radiotherapy ; Radiotherapy, Adjuvant/adverse effects ; Randomized Controlled Trials as Topic ; Sarcoma, Ewing/pathology ; Sarcoma, Ewing/radiotherapy
Language	English
Publishing date	2002-01
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	1025984-3
ISSN	1569-8041 ; 0923-7534
ISSN (online)	1569-8041
ISSN	0923-7534
DOI	10.1093/annonc/mdf047
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2862: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.

Janinis, J / Papadakou, M / Xidakis, E / Boukis, H / Poulis, A / Panagos, G / Lefantzis, D

American journal of clinical oncology

2000 Volume 23, Issue 2, Page(s) 128–131

Abstract: The purpose of this phase II feasibility trial was to determine the efficacy and toxicity of docetaxel combined with cisplatin and 5-fluorouracil in patients with locally advanced and/or recurrent squamous cell carcinoma of the head and neck. Nineteen ... ...

Abstract	The purpose of this phase II feasibility trial was to determine the efficacy and toxicity of docetaxel combined with cisplatin and 5-fluorouracil in patients with locally advanced and/or recurrent squamous cell carcinoma of the head and neck. Nineteen patients entered the study. The majority had received prior radiotherapy but were chemotherapy naive. Treatment consisted of docetaxel 80 mg/m2 day 1, cisplatin 40 mg/m2 days 2 and 3, and 5-fluorouracil 1,000 mg/m2 by continuous infusion days 1 to 3. The cycle was repeated every 28 days. Most patients received granulocyte colony-stimulating factor, 150 microg/m2/day subcutaneously between days 4 and 8. The median number of chemotherapy cycles per patient was four. Dose reduction was done in three patients with no treatment delays. Of the 16 evaluable for response, seven patients (44%) demonstrated an objective response, including two complete and five partial ones; eight patients (50%) had stable disease; and one patient had progressive disease. The median time to progression was 7.5 months (range: 4-17.5 months). The median survival was 11 months (range: 1-18 months) and 1-year survival was 49%. Febrile neutropenia was recorded in 15% of courses. There were no toxic deaths. In conclusion, the combination of docetaxel, cisplatin, and 5-fluorouracil is an active regimen against previously treated squamous cell carcinoma of the head and neck with acceptable toxicity.
MeSH term(s)	Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/pathology ; Cisplatin/administration & dosage ; Disease Progression ; Disease-Free Survival ; Docetaxel ; Feasibility Studies ; Female ; Fluorouracil/administration & dosage ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/pathology ; Humans ; Male ; Middle Aged ; Neutropenia/chemically induced ; Paclitaxel/administration & dosage ; Paclitaxel/analogs & derivatives ; Recurrence ; Taxoids
Chemical Substances	Taxoids ; Docetaxel (15H5577CQD) ; Paclitaxel (P88XT4IS4D) ; Cisplatin (Q20Q21Q62J) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2000-04
Publishing country	United States
Document type	Clinical Trial ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	604536-4
ISSN	1537-453X ; 0277-3732
ISSN (online)	1537-453X
ISSN	0277-3732
DOI	10.1097/00000421-200004000-00005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1557: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito